Category: news

CSafe Global, a leading provider of active and passive temperature-controlled solutions for pharmaceutical products, is pleased to announce that United Cargo, one of the industry’s leading air cargo brands, has approved the recently launched CSafe RAP for in-flight use on its fleet.
Dayton, OH—The CSafe RAP is the latest innovation in a full line of temperature control solutions, offering unmatched operational capabilities with the industry’s largest RAP payload capacity to ensure successful large-volume shipments of temperature-sensitive pharmaceuticals across the globe.
United Cargo today announced it will enhance its TempControl service and expand the options it offers shippers of pharmaceuticals and other life science products by approving the new CSafe RAP active container.
The CSafe RAP utilizes innovative heating and compressor-driven cooling technologies, along with advanced ThermoCor VIP insulation, to maintain constant payload temperatures even at extreme ambient temperatures spanning from -30°C to +54°C – the broadest operating range in the industry. Its large payload compartment of 6.68m3 easily accommodates up to four standard U.S. pallets or five standard Euro pallets. With an extended battery run time of over 120 hours, the CSafe RAP ensures temperature integrity and product viability through to destination even on extended journeys.
“The CSafe RKN container has been a key component of our TempControl service since 2010,” said Jan Krems, President of United Cargo. “The demand for pharmaceuticals and other health care products grows every year, and customers and patients worldwide are seeking expanded capacity across our TempControl network. With the new CSafe RAP, we can meet this need using the innovative CSafe technology that is proven by years of impeccable performance and trusted by our customers.”
“CSafe is very excited to add United Cargo to the ever-expanding list of airlines that have approved our new CSafe RAP temperature-controlled container,” stated Jeff Pepperworth, CEO of CSafe Global. “The combination of United Cargo’s expansive TempControl network and the superior performance of the CSafe RAP container offers life-science companies a powerful and reliable solution to move temperature-sensitive healthcare products to patients across the globe.”
Many of the same leasing options currently available for the CSafe RKN are available for the new CSafe RAP container. Customers may lease the CSafe RAP container directly from CSafe Global or through United Cargo.
Customers seeking more information about the CSafe RAP or their leasing options should visit www.csafeglobal.com/csafe-rap or contact their United Cargo Sales Professional.

Collaborative effort will accelerate development of novel therapies for underserved diseases involving the central nervous system.
SAINT PAUL, MINN. – Minnetronix Neuro, a division of Minnetronix Medical, today announced that it has co-founded The Neurapheresis Consortium with Duke University. Designed to bring together leading researchers and clinicians, the consortium will accelerate the advancement of Neurapheresis Therapy, intended to improve outcomes for multiple, underserved patient populations, suffering from diseases involving infectious, inflammatory and neurodegenerative agents in the central nervous system.
Working in partnership with disease experts across the globe, Nandan Lad, M.D., Associate Professor of Neurosurgery at Duke, will lead the consortium’s efforts to advance Neurapheresis Therapy through pre-clinical research, and ultimately into the clinic for multiple indications. Neurapheresis Therapy is built on a proprietary technology platform developed by Minnetronix Neuro that is designed to prevent secondary injury and enhance healing by removing disease causing agents from the cerebral spinal fluid.
“We are building an exceptional team of global disease and medical technology experts to advance our research and develop truly novel therapies,” said Lad. “The Neurapheresis Consortium will unite the world’s leading authorities on specific disease states, medical technology experts and organizations that support grant-based funding, to help us deliver meaningful solutions to patients suffering from debilitating and life-threatening neurological conditions.”
Minnetronix Neuro will bring significant product development expertise to the consortium. The company began building its portfolio following the acquisition of patented technology that it developed into the Neurapheresis Therapy. Aaron McCabe Ph.D., head of research and development for Minnetronix Neuro, will provide nearly twenty years of medtech industry experience to the consortium.
“Our goal is simple: To improve outcomes for neuro patients who currently have few, if any, treatment options,” said Matt Adams, Minnetronix Neuro General Manager. “The Neurapheresis Consortium represents a powerful force of knowledge, skill and determination that will help transform the very real needs of patients suffering from neurological disease into life-enhancing solutions.”
About Neurapheresis Therapy
Neurapheresis Therapy is a platform technology in a portfolio of proprietary solutions being developed by Minnetronix Neuro for the Neuro ICU. During this minimally invasive process, a dual lumen catheter is placed in the lumbar spine, and contaminated CSF is actively filtered to rapidly remove blood and blood breakdown byproducts. Clean CSF is simultaneously returned to the patient. Neurapheresis Therapy is considered a breakthrough treatment option for aneurysmal subarachnoid hemorrhage patients, with the potential to significantly advance the current standard of care, improve outcomes for patients and minimize the impact of aSAH on the healthcare system. Neurapheresis Therapy is an investigational device, limited by Federal law to investigational use. More information about Neurapheresis Therapy and the Neurapheresis Consortium is available at www.neurapheresis.org
About Minnetronix Neuro
Minnetronix Neuro, a division of Minnetronix Medical, is developing a portfolio of solutions designed to prevent secondary injury and enhance healing for patients in the Neuro ICU. The company is focused on delivering cost-effective solutions for physicians and patients to advance treatment options and improve outcomes. www.minnetronixmedical.com

NASHVILLE, Tenn.–(BUSINESS WIRE)–Clearwater, a top-ranked healthcare cyber risk management solutions company, announced today that the NIST Special Publication (SP) 1800-8: “Securing Wireless Infusion Pumps in Healthcare Delivery Organizations used Clearwater’s IRM|Analysis™ software to conduct the information risk assessment of several major infusion pumps. As stated in the NIST publication’s section on Risk Assessment and Mitigation, “we used the Clearwater IRM|Analysis™ Software-as-a-Service (SaaS) application, a control-based risk tool, for conducting a risk assessment focused on the HDO enterprise.”
In conjunction with IRM|Analysis, the NCCoE analyzed risk factors in and around the infusion pump ecosystem and, with the results of that assessment, developed an example implementation that demonstrates how healthcare organizations can reduce cybersecurity risk, potentially reduce impact to patient safety, and implement current cybersecurity standards and best practices while maintaining the performance and usability of wireless infusion pumps. The NCCoE is a collaborative hub where industry organizations, government agencies, and academic institutions work together to address businesses’ most pressing cybersecurity challenges.
“We are honored to be one of NCCoE’s many technology collaborators and to have contributed our IRM|Analysis enterprise cyber risk management software and subject matter expertise to this important effort,” said Clearwater CEO Steve Cagle. “Healthcare delivery organizations will want to use this best-practice guide in taking immediate steps to help alleviate potential threats to wireless infusion pumps.”
Section 2.5.2 of the NIST special publication states: “This section does not show you how to conduct a risk assessment. Instead, we present some basic steps for using the tool to conduct the risk assessment.” The steps include creating an inventory of information assets, establishing conformance with NIST-based security controls, determining the risk rating with likelihood and impact assessments, identifying risks that exceed the established risk threshold, and utilizing risk responses and dashboard reporting.
NIST Special Publication 1800-8 demonstrates how biomedical engineers and IT professionals can utilize technologies that are consistent with cybersecurity standards to help securely configure and deploy wireless infusion pumps within HDOs.
The final NIST publication is available for download on the NCCoE website.
About Clearwater
Clearwater provides the most complete and trusted, enterprise-class cyber risk management solution available. Designed for healthcare providers and their partners, Clearwater’s IRM|Pro™ platform and experienced professional services team provide insights and actions to address compliance, cyber and patient safety risks. Clearwater is a 2017 Inc. 5000 fastest-growing company, the 2018 Best in KLAS winner in Cybersecurity Advisory Services, the 2017 and 2018 Black Book Marketing Research winner in Compliance and Risk Management Solutions, and exclusively endorsed by the American Hospital Association as well as numerous state hospital associations. Clearwater solutions have been deployed within hundreds of hospitals and health systems, Fortune 100 organizations, and federal government institutions. More information about Clearwater is at www.Clearwatercompliance.com.
Contacts
Clearwater
Kelly Motley, 615-483-0365
Kelly.Motley@Clearwatercompliance.com

Minnetronix Neuro, a division of Minnetronix Medical, Inc., today announced the completion of their first sponsored, multicenter study of their novel Neurapheresis™ Therapy, the PILLAR trial. Spiros Blackburn, M.D. will present the summary data during the Late Breaking Science session at the Congress of Neurological Surgeons annual meeting taking place in Houston October 6-10th. Dr. Blackburn, a neurosurgeon specializing in cerebrovascular and skull base surgery at Memorial Hermann in Houston, served as principal investigator for the lead enrolling site in the study.
The PILLAR study evaluated the safety, tolerability, and feasibility of Neurapheresis Therapy in patients suffering from aneurysmal subarachnoid hemorrhage (aSAH). This innovative new therapy is designed to facilitate the removal of targeted contaminants in the cerebral spinal fluid (CSF). In the case of an aSAH event, Neurapheresis Therapy targets removal of blood and blood byproducts remaining in the CSF following aneurysm securement with the goal of minimizing the inflammatory cascade caused by their presence. “There is a significant unmet need for effective treatment options for subarachnoid hemorrhage patients and I am really encouraged by the therapy’s potential to improve patient outcomes,” said Christa Swisher, M.D., Neurointensivist and site principal investigator for the study at Duke Health.
About Neurapheresis Therapy
Neurapheresis Therapy is a platform technology in a portfolio of proprietary solutions being developed by Minnetronix Neuro for the Neuro ICU. During this minimally invasive process, a dual lumen catheter is placed in the lumbar spine, and contaminated CSF is actively filtered to rapidly remove blood and blood breakdown byproducts. Clean CSF is simultaneously returned to the patient. Neurapheresis Therapy is considered a breakthrough treatment option for aSAH patients, with the potential to significantly advance the current standard of care, improve outcomes for patients and minimize the impact of aSAH on the healthcare system. Neurapheresis Therapy is an investigational device, limited by Federal law to investigational use.
About Minnetronix
Neuro Minnetronix Neuro, a division of Minnetronix Medical, is developing a portfolio of solutions designed to prevent secondary injury and enhance healing for patients in the Neuro ICU. The company is focused on delivering cost-effective solutions for physicians and patients to advance treatment options and improve outcomes.

NEWARK, N.J. and CHENNAI, India, Sept. 18, 2018 /PRNewswire/ — AGS Health Inc., a global healthcare revenue cycle management company has been named for the third year in a row to the prestigious 2018 100 Best Companies for Women in India (BCWI) list produced by AVTAR Group and Working Mother Media. Currently in its third edition after a highly successful run in 2016 and 2017, the BCWI Study aims to recognize and bring into foray the sustained initiatives undertaken by companies to increase women’s workforce participation.
“The exemplary companies that made the 2018 100 Best Companies for Women in India list represent the most progressive companies for women. We applaud their vision and efforts to create and sustain a work environment where women can advance and thrive.” said Subha Barry, President, Working Mother Media.
The 2018 edition had 345 companies participating across industries, who were assessed across multiple criteria such as workforce demographics, recruitment, retention and career advancement programs, safety and security initiatives, benefits, culture, leave and flexible work, and work-life programs.
“We are honored to be listed once again amongst the 100 Best Companies for Women in India. The award is a testimony to our relentless commitment to diversity and inclusion, and we thank all our colleagues who make our Company a great place to work,” said Devendra Saharia, CEO of AGS Health
Commenting on the initiative, Dr. Saundarya Rajesh, Founder – President, AVTAR Group, said “To see organizations evolve their enablement framework to one that acknowledges and supports the holistic well-being of employees, specifically women, is extremely heartening. Offering such support especially at critical life events like maternity helps women professionals navigate emotion hurdles and build successful, sustainable careers. With personalized handholding, their engagement with their employers are heightened and growth to leadership is a natural, logical extension. The 2018 BCWI data tells us just that.”
About AGS Health
AGS Health is an analytics driven, technology enabled Revenue Cycle Management Company providing services to leading healthcare providers across the U.S. With a global workforce of over 5000 billing and coding specialists, AGS Health has been ranked as the 12th Largest Revenue Cycle Firm in the US by Modern Healthcare, and among the Top 100 Global Outsourcing Companies in the World by the International Association of Outsourcing Professionals (IAOP).
For more details, please visit www.agshealth.com
Contact
Smita Venkataraman, 855-304-0434
PRNewswire.

Clearwater, a healthcare cyber risk management solutions company, announced the release of CyberIntelligence dashboards, the latest innovation for IRM|Pro, an Enterprise Cyber Risk Management System (ECRMS) for healthcare providers and their partners. With CyberIntelligence dashboards, organizations can elevate cyber risk conversations from a technical engineering discussion to an actionable, executive or board-level one—advancing healthcare organizations’ cyber risk management programs, reducing risk and increasing patient safety.
CyberIntelligence dashboards, available immediately for customers subscribing to Clearwater’s IRM|Analysis software, provide actionable insight into the most critical vulnerabilities, control deficiencies, and remediation action items, allowing organizations ranging from regional hospitals to the largest integrated delivery networks to effectively manage risk across their entire enterprise. IRM|Analysis implements the HHS Office for Civil Rights’ guidance for Security Risk Analysis, harnesses the power of the NIST risk assessment process and fulfills the requirements of the HIPAA Security and Privacy Rules. IRM|Analysis is used by more than 400 healthcare companies including IDNs such as CHRISTUS Health, Sentara Healthcare, OhioHealth, and Baptist Health South Florida.
According to the Ponemon Institute’s The State of Cybersecurity in Healthcare Organizations in 2018, sponsored by Merlin: “Legacy systems and disruptive technologies, such as cloud, mobile, big data and Internet of Things, put patient information at risk. More organizations consider legacy systems as a serious risk to patient information (58% of respondents vs. 52% of respondents in 2016). In addition, new technologies and trends such as the cloud, mobile, big data and the Internet of Things are increasing the vulnerability and threats to patient information (57% of respondents vs. 51% of respondents). More respondents are concerned about the effectiveness of third-party contracts to secure patient information.”
CyberIntelligence provides boards and CEOs with real-time visibility to the greatest cyber risks across the growing landscape of technologies, enabling organizations to identify and take action on the most critical needs. As a result, they can maximize the effect of limited resources and budgets to ensure the most optimal results.

NEW YORK — The Transportation Security Administration (TSA), working collaboratively with American Airlines, is demonstrating a new computed tomography (CT) scanner at the Terminal 8 security checkpoint at New York’s John F. Kennedy International Airport (JFK).
State-of-the-art CT checkpoint technology is an enhancement to today’s two-dimensional (2-D) X-ray technology platforms scanning equipment, which is used at the majority of security checkpoints worldwide. Because CT technology is three dimensional (3-D), this new checkpoint technology has the potential to provide better visibility and allow the operator to rotate the bag’s image 360 degrees to show the contents of carry-on items at every angle. CT provides the capability to virtually see beyond unwanted clutter and greatly enhances the ability to visually inspect the contents of carry-on bags for explosives and other prohibited items.
CT technology improves detection capability by more effectively detecting threats, thereby increasing overall security effectiveness. This results in more effective security screening at the security checkpoint. In the future, CT could offer the opportunity for passengers to leave liquids, gels and aerosols, as well as laptops, in their carry-on bags at all times.
Deployment of this technology, both in the United States and abroad, is a critical component of raising the global aviation security baseline.
“Use of CT technology substantially improves TSA’s threat detection capability at a checkpoint.” said TSA Administrator David Pekoske. “This partnership will allow us to deploy new technology quickly and see an immediate improvement in security effectiveness.”
“At American, we are always looking at ways to invest in technology that raises the bar on global aviation security while improving the customer experience,” said American Airlines Chief Security Officer José Freig. “Our partnership with Analogic Corporation and the TSA will continue to transform aviation security by bringing state-of-the-art CT technology to the security checkpoint.”
TSA expects the new CT technology will begin operation at JFK in late July. CT technology is also being tested at airport security checkpoints in Phoenix and Boston.
About American Airlines Group
American Airlines and American Eagle offer an average of nearly 6,700 flights per day to nearly 350 destinations in more than 50 countries. American has hubs in Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix and Washington, D.C. American is a founding member of the oneworld® alliance, whose members serve nearly 1,000 destinations with 14,250 daily flights to 150 countries. Shares of American Airlines Group Inc. trade on Nasdaq under the ticker symbol AAL. In 2015, its stock joined the S&P 500 index. Connect with American on Twitter @AmericanAir and at Facebook.com/AmericanAirlines.

CSafe Global, a leading provider of active and passive temperature-controlled solutions for pharmaceutical products, is pleased to announce that Turkish Cargo, one of the industry’s fastest growing air cargo brands, has approved the recently launched CSafe RAP for in-flight use on its fleet.
Dayton, Ohio – July 18, 2018
The CSafe RAP is the latest innovation in a full line of temperature control solutions, offering unmatched operational capabilities with the industry’s largest RAP payload capacity to ensure successful large-volume shipments of temperature-sensitive pharmaceuticals across the globe.
“Turkish Cargo have long been experts when it comes to transporting temperature-sensitive healthcare products globally,” said Brad Jennings, VP of Global Marketing and Partner Management for CSafe Global. “CEIV accreditation further demonstrates their commitment to providing our mutual life-science customers with precision cold-chain services that have been validated to exceptionally high standards.”
“The CSafe RAP will be an excellent addition of active temperature-controlled containers being used for transportation of healthcare products in the Turkish Cargo pharma program. With volumes of pharmaceutical shipments growing on a global scale, active temperature-controlled containers for larger cargo payloads are required. The CSafe RAP will give Turkish Cargo the ability to continue to provide best-in-class service to our customers around the world, meeting their expectations in terms of volume, cargo integrity and safety, and on time transportation. Partnership with CSafe Global, the company that shares the same customer-centric values and business attitudes as we do, provides Turkish Cargo with confidence in the preservation and integrity of our shipments, every single time,” said Senior Vice President, Cargo Marketing, Mr. Fatih Cigal.
The new CSafe RAP delivers on a quality promise, ensuring the temperature integrity and safe delivery of temperature-sensitive, life-enhancing products for healthcare companies worldwide. The CSafe RAP active container system leverages the proven performance and capabilities of the well-established CSafe RKN to remove the operational and environmental challenges encountered with global temperature-controlled shipments. By utilizing CSafe’s proprietary ThermoCor VIP insulation together with a compressor-driven cooling and radiant heating system, the CSafe RAP precisely maintains the user-defined payload temperature set point through payload transport, regardless of ambient conditions.

G&H Orthodontics is a full line manufacturer of orthodontic products. G&H has supplied Orthodontists worldwide with the best products on the market for over 40 years. We are proud of the reputation that we have garnered in the industry and continue to look for ways to bring quality products to our customers. For this reason, we are excited to announce our collaboration with Premier Dental, and to offer our customers even more outstanding treatment options.
For over a century, Premier Dental has provided innovative, standard-setting products that help dental professionals perform their craft at the highest level. Premier’s inspired solutions are not only a perfect complement to Orthodontists focused on delivering a terrific outcome on the Great Big Day…they’re also an indispensable part of ensuring patients enjoy an entire lifetime of happy, healthy smiles. With an award-winning stable of products including Enamel Pro^® Prophy paste with Amorphous Calcium Phosphate (ACP), the versatile 2pro^® prophy angles, Enamel Pro^® Varnish, Alfa™ Triple Trays^®, the Perfecta^® REV!^® whitening system and Enamelon^®, Premier’s product suite is a terrific fit with G&H. Premier Dental CEO Julie Charlestein announced, “Premier is proud to partner with G&H as our companies have a shared mission to deliver unsurpassed oral care health solutions to our customers and great outcomes to their patients. Whether it’s helping patients look their absolute best on their Great Big Day, or equipping them with the products and hygiene regimen to keep their smiles bright and healthy on their journey forward, Premier is thrilled to play an important role alongside G&H.”
Patients, parents, Orthodontists, G&H Orthodontics, and Premier Dental are all invested in bringing healthy smiles to life. That is what this business is all about – to create great big days for every patient out there. Kevin McNulty, CEO of G&H Orthodontics, agrees noting, “Nothing touched my heart more than seeing that first smile when my children had their Great Big Day! At G&H, we are very grateful to play a part in this moment and we thank our doctors for trusting us with their masterpieces.”
About G&H Orthodontics
G&H Orthodontics, Inc. is a leading provider of clinical solutions for the orthodontic community serving customers for over 40 years in over 90 countries. G&H^® is the manufacturer of a full line made in the U.S.A. including brackets, bands, tubes, wires, springs, elastomerics, and other orthodontic supplies. G&H is compliant with the U.S. FDA, ISO 13485:2003, Medical Device Directives, 93/42 EEC and Canadian Medical Device Guidelines, which ensures availability of products worldwide. G&H Orthodontics is a privately held company headquartered in Franklin, Indiana.
About Premier^® Dental
Premier Dental is a global privately held developer and manufacturer of dental products with sales in over 75 countries. Dental professionals have turned to Premier for over 100 years to improve their daily procedures and practices. A leader in bringing innovative products to market, Premier is dedicated to inspired solutions for daily dentistry. To learn more about Premier Dental’s inspired solutions for daily dentistry, visit www.premusa.com.
Contact
Heidi Kienholz, Marketing Manager
G&H Orthodontics
hkienholz@ghortho.com

PEABODY, Mass. – July 5, 2018 – Analogic Corporation, a leading provider of advanced imaging technologies to the medical imaging and security industries, today announced and welcomed the addition of Mr. Tom Ripp as president of Security and Detection. In this newly created position, Mr. Ripp will lead Analogic’s Security and Detection division, which is a global leader in the automated threat detection industry.
Fred Parks, president and CEO, commented, “We are excited to welcome Tom to the Analogic family and know his experience and expertise in the security industry will be extremely valuable as we continue to grow our business, find new and exciting applications for our leading-edge technologies, and deepen our relationships with customers.”
Prior to Analogic, Mr. Ripp served as senior vice president of Security Solutions at L3 Technologies and brings over a decade of experience working with OEMs, airlines, airports and regulators around the world.
“I am thrilled to join Analogic at this exciting time in the company’s history,” Mr. Ripp added. “Analogic has a legacy for innovation and advanced technology solutions and I look forward to continuing the company’s commitment to serving its OEM customers, as well as expanding and innovating its threat detection solutions in new markets.”
About Analogic
Analogic provides leading-edge healthcare and security technology solutions to advance the practice of medicine and save lives. We are recognized around the world for advanced imaging and real-time guidance technologies used for disease diagnosis and treatment as well as for automated threat detection. Our market-leading ultrasound systems, led by our flagship BK Ultrasound brand, used in procedure-driven markets such as urology, surgery, and point-of-care, are sold to clinical practitioners around the world. Our advanced imaging technologies are also used in computed tomography (CT), magnetic resonance imaging (MRI), and digital mammography systems, as well as automated threat detection systems for aviation security. Analogic is headquartered just north of Boston, Massachusetts. For more information, visit www.analogic.com.